• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

    4/23/25 8:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RYTM alert in real time by email

    BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and provide a corporate update.

    To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start.

    A webcast of the call will also be available under "Events and Presentations" in the Investor Relations section of the Rhythm Pharmaceuticals website at https://ir.rhythmtx.com/. The archived webcast will be available on Rhythm Pharmaceuticals' website approximately two hours after the conference call and will be available for at least 30 days following the call.

    About Rhythm Pharmaceuticals

    Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm's lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. Both the European Commission (EC) and the UK's Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm's headquarters is in Boston, MA.

    Setmelanotide Indication

    In the United States, setmelanotide is indicated to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).

    In the European Union and the United Kingdom, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. In the European Union and the United Kingdom, setmelanotide should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.

    Limitations of Use

    Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective:

    • Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign
    • Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity

    Contraindication

    Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.

    WARNINGS AND PRECAUTIONS

    Disturbance in Sexual Arousal: Spontaneous penile erections in males and sexual adverse reactions in females have occurred. Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.

    Depression and Suicidal Ideation: Depression, suicidal ideation and depressed mood have occurred. Monitor patients for new onset or worsening depression or suicidal thoughts or behaviors. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur.

    Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue IMCIVREE.

    Skin Hyperpigmentation, Darkening of Pre-existing Nevi, and Development of New Melanocytic Nevi: Generalized or focal increases in skin pigmentation, darkening of pre-existing nevi, development of new melanocytic nevi and increase in size of existing melanocytic nevi have occurred. Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new pigmented lesions.

    Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates and Low Birth Weight Infants: IMCIVREE is not approved for use in neonates or infants. Serious and fatal adverse reactions including "gasping syndrome" can occur in neonates and low birth weight infants treated with benzyl alcohol preserved drugs.

    ADVERSE REACTIONS

    Most common adverse reactions (incidence ≥20%) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection.

    USE IN SPECIFIC POPULATIONS

    Treatment with IMCIVREE is not recommended when breastfeeding. Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.

    To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See section 4.8 of the Summary of Product Characteristics for information on reporting suspected adverse reactions in Europe.

    Please see the full Prescribing Information for additional Important Safety Information.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the release of our financial results and our participation in upcoming events and presentations, including the timing of any of the foregoing. Statements using words such as "expect", "anticipate", "believe", "may", "will" and similar terms are also forward-looking statements. Such statements are subject to numerous risks, uncertainties and other important factors, including those discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 and our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

    Corporate Contact:

    David Connolly

    Head of Investor Relations and Corporate Communications

    Rhythm Pharmaceuticals, Inc.

    857-264-4280

    [email protected]

    Media Contact:

    Sheryl Seapy

    Real Chemistry

    (949) 903-4750

    [email protected]  



    Primary Logo

    Get the next $RYTM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RYTM

    DatePrice TargetRatingAnalyst
    4/7/2025$63.00Neutral → Buy
    BofA Securities
    3/5/2025$78.00Buy
    Stifel
    1/2/2025$80.00Buy
    Jefferies
    12/20/2024$76.00Outperform
    Oppenheimer
    10/21/2024$70.00Buy
    Guggenheim
    9/18/2024$64.00Buy
    H.C. Wainwright
    9/17/2024$64.00Mkt Outperform
    JMP Securities
    5/8/2024$49.00 → $42.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $RYTM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Rhythm Pharmaceuticals Inc.

      SC 13G - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      11/14/24 9:50:26 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rhythm Pharmaceuticals Inc.

      SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      11/14/24 5:46:11 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rhythm Pharmaceuticals Inc.

      SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      11/12/24 5:23:38 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

      -- First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity -- -- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 -- -- Topline data from Phase 2 trial of oral MC4R agonist bivamelagon on track to be announced in third quarter of 2025 -- -- Cash on-hand expected to support planned operations into 2027 -- -- Management to host conference call today at 8:00 a.m. ET -- B

      5/7/25 7:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

      BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at three upcoming investor conferences: Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 at 12:20 a.m. ETJefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 3:10 p.m. ETGoldman Sachs Annual Healthcare Conference on Monday, June 9, 2025 at 8:00 a.m. ET The fireside chats will be webcasted and availab

      5/6/25 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

      BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and provide a corporate update. To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. A webcast of the call will also be available under "Events and Presentations" in the Invest

      4/23/25 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $RYTM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chief Human Resources Officer Cramer Pamela J. sold $457,663 worth of shares (7,031 units at $65.09) and exercised 7,031 shares at a strike of $6.80 (SEC Form 4)

      4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

      5/1/25 4:53:44 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Head of International Mazabraud Yann sold $438,946 worth of shares (6,745 units at $65.08), decreasing direct ownership by 15% to 37,655 units (SEC Form 4)

      4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

      5/1/25 4:52:53 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Head of International Mazabraud Yann converted options into 21,780 shares, increasing direct ownership by 96% to 44,400 units (SEC Form 4)

      4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

      4/16/25 4:30:22 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals upgraded by BofA Securities with a new price target

      BofA Securities upgraded Rhythm Pharmaceuticals from Neutral to Buy and set a new price target of $63.00

      4/7/25 12:20:34 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel resumed coverage on Rhythm Pharmaceuticals with a new price target

      Stifel resumed coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $78.00

      3/5/25 7:44:16 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Rhythm Pharmaceuticals with a new price target

      Jefferies initiated coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $80.00

      1/2/25 8:06:46 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    SEC Filings

    See more
    • SEC Form 10-Q filed by Rhythm Pharmaceuticals Inc.

      10-Q - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

      5/7/25 4:46:19 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

      5/7/25 7:01:40 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Rhythm Pharmaceuticals Inc.

      DEFA14A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

      4/29/25 4:01:46 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Leadership Updates

    Live Leadership Updates

    See more
    • Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

      BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair "Al" Garfield, Ph.D. as Chief Scientific Officer, effective July 1. "We are excited to welcome Al back to Rhythm as we continue to leverage our understanding of the melanocortin-4 receptor (MC4R) pathway to bring potential therapies to patients and their families," said David Meeker, M.D., Rhythm Chairman, Chief Executive Officer and President. "Al's leadership and established scientific expertise and experience

      7/8/24 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

      BOSTON, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced the appointment of Dana Washburn, M.D., as Senior Vice President of Clinical Development and as a member of the Company's Executive Leadership Team, effective September 26, 2022. As SVP of Clinical Development, Dr. Washburn will lead the Company's robust clinical development program, clinical operations, and data management. "Dr. Washburn is a collaborative, resourceful leade

      10/6/22 4:02:00 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wren Appoints Bart Henderson as Chief Executive Officer

      Wren Therapeutics, a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, today announced the appointment of Bart Henderson as Chief Executive Officer. Wren's unique drug discovery platform harnesses advances in the biophysics of protein assembly dynamics to target the toxic fleeting protein intermediates, the oligomers, in neurodegenerative disease pathways, and discover small molecules that can block their generation with precision. Bart brings broad leadership experience in the biotechnology industry as a founder and co-founder of several companies including Torque (now Repertoire Immune Medicines), Rhythm (NASDAQ:RYTM) and its subsidiary Motus (acquired

      3/4/22 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Financials

    Live finance-specific insights

    See more
    • Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

      -- First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity -- -- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 -- -- Topline data from Phase 2 trial of oral MC4R agonist bivamelagon on track to be announced in third quarter of 2025 -- -- Cash on-hand expected to support planned operations into 2027 -- -- Management to host conference call today at 8:00 a.m. ET -- B

      5/7/25 7:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

      BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and provide a corporate update. To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. A webcast of the call will also be available under "Events and Presentations" in the Invest

      4/23/25 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

      -- Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks (p<0.0001) -- -- -19.2% placebo-adjusted BMI reduction achieved in adult patients 18 years old and older (n=49) at 52 weeks -- -- -20.2% placebo-adjusted BMI reduction achieved in patients younger than 18 years old (n=71) at 52 weeks -- -- Regulatory submissions in the U.S. and EU anticipated to be completed in the third quarter of 2025 -- -- Company to host conference call today at 8 a.m. ET -- BOSTON, April 07, 2025 (GLOBE NEWSWIRE) --  Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage bi

      4/7/25 7:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care